BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BioNexus Gene Lab's ebitda for the twelve months ending Dec 31, 2019 was -$233.99K, down 332.8% year over year. For fiscal 2019 it was -$233.99K, down 332.8% from the year before.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -$233.99K | -332.8% |
| FY2018 | Dec 31, 2018 | $100.51K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | -$85.73K | – |
| Q3 FY2019 | Sep 30, 2019 | -$39.80K | – |
| Q4 FY2018 | Dec 31, 2018 | -$53.51K | – |
| Q3 FY2018 | Sep 30, 2018 | -$45.17K | – |
See a number that looks wrong?